Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Organovo Hol ...

Onvo Stock- Organovo's stock jumps 200% after Eli Lilly acquires its FXR program, including the promising IBD treatment ...

SAN DIEGO, CA, USA I5, 2025 I Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused ...

Eli Lilly (LLY) on Wednesday outlined a plan to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the US. The pharmaceutical giant said that three of the planned ...

China needs to tackle its steel glut by cutting 15% of capacity this year, if mills are to meet their 2025 climate goals and ...

Short interest in Organovo Holdings Inc (NASDAQ:ONVO) decreased during the last reporting period, falling from 78.04K to 71.89K. This put 0.48% of the company's publicly available shares short.